Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of alisertib and romidepsin in
treating patients with B-cell or T-cell lymphomas that have returned after a period of
improvement (relapsed) or have not responded to treatment (refractory). Alisertib and
romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.